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Abstract
Interferon regulatory factor (IRF)-1 is an immunomodulatory transcription factor that functions downstream of pathogen
recognition receptor signaling and has been implicated as a regulator of type I interferon (IFN)-ab expression and the
immune response to virus infections. However, this role for IRF-1 remains controversial because altered type I IFN responses
have not been systemically observed in IRF-1
-/- mice. To evaluate the relationship of IRF-1 and immune regulation, we
assessed West Nile virus (WNV) infectivity and the host response in IRF-1
-/- cells and mice. IRF-1
-/- mice were highly
vulnerable to WNV infection with enhanced viral replication in peripheral tissues and rapid dissemination into the central
nervous system. Ex vivo analysis revealed a cell-type specific antiviral role as IRF-1
-/- macrophages supported enhanced WNV
replication but infection was unaltered in IRF-1
-/- fibroblasts. IRF-1 also had an independent and paradoxical effect on CD8
+
T cell expansion. Although markedly fewer CD8
+ T cells were observed in naı ¨ve animals as described previously, remarkably,
IRF-1
-/- mice rapidly expanded their pool of WNV-specific cytolytic CD8
+ T cells. Adoptive transfer and in vitro proliferation
experiments established both cell-intrinsic and cell-extrinsic effects of IRF-1 on the expansion of CD8
+ T cells. Thus, IRF-1
restricts WNV infection by modulating the expression of innate antiviral effector molecules while shaping the antigen-
specific CD8
+ T cell response.
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Introduction
The rapid triggering of an IFN-ab response results in the early
control of virus infection in mammalian cells. Detection of RNA
viruses occurs through the recognition of specific sequence motifs,
secondary structure, or modification of viral nucleic acids by
pattern recognition receptors (PRR) in the cytosol (RIG-I and
MDA5) and endosome (TLR3, TLR7, and TLR8) [1]. PRR
binding of viral RNA signals constituent adaptor molecules (IPS-1,
TRIF, and MyD88) to activate transcription factors and induce
expression of IFN-ab genes. A current paradigm for IFN
production after RNA virus infection describes a positive feedback
model that is modulated by the transcription factors interferon
regulatory factors (IRF)-3 and IRF-7 [2,3]. In the initial phase,
viral nucleic acid sensing induces nuclear localization of IRF-3,
which stimulates gene transcription and production of IFN-b and
IFN-a4 by infected cells. In the second phase, these IFNs bind to
the common IFN-ab receptor in a paracrine and autocrine
manner and signal through the JAK-STAT pathway resulting in
the induced expression of hundreds of interferon stimulated genes
(ISG) (e.g., PKR, RNAse L, viperin, ISG15, ISG54, ISG56,
IFITM3, and ISG20), which limit viral replication through
multiple mechanisms [4,5,6,7,8,9]. IRF-7 is both an ISG and a
transcriptional activator and participates in an IFN amplification
loop by inducing IFN-b and many subtypes of IFN-a [3,10].
West Nile virus (WNV) is a single-stranded positive polarity
RNA virus in the Flaviviridae family that cycles in nature between
birds and Culex mosquitoes. Humans, which are dead-end
incidental hosts, can develop a febrile illness that progresses to
flaccid paralysis, meningitis, or encephalitis [11]. WNV is
emerging in the Western hemisphere as greater than 30,000
human cases of severe infection have been diagnosed in the United
States since 1999, and millions have been infected and remain
undiagnosed [12]. Experiments in mice have identified immune
mechanisms of control with significant contributions from
inflammatory cytokines, chemokines, complement, B CD4
+, and
CD8
+ T cells (reviewed in [13,14]). In particular, type I IFN (IFN-
ab) has an essential function in restricting cell and tissue tropism as
IFN-abR
-/- or IFN-b
-/- mice rapidly succumb to WNV infection
[15,16,17].
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 Although IFN-b shapes a response that restricts WNV infection
inmanycellsandtissues,itsinductionappearstodifferina celltype-
dependent manner. In fibroblasts and neurons, IFN-b is triggered
through an IPS-1-dependent and IRF-3 and IRF-7-dependent
transcriptional signal [10,18]. However, additional transcription
factors contribute to the regulation of IFN-b as gene expression and
protein production were preserved in IRF-3
-/- x IRF-7
-/- myeloid
cells after WNV infection [19]. Based on these studies, we
hypothesized that additional transcriptional factors could regulate
IFN-b and/or ISG expression. In particular, the function of IRF-1
in the context of infection by WNV or other flaviviruses remained
unknown. We viewed IRF-1 as a candidate transcription factor
because it had been reported to contribute to IFN-b induction in
some experimental systems. IRF-1 was initially identified as a
Newcastle disease virus (NDV)-induced transcription factor that
activated IFN-b gene transcription in cell culture [20,21,22]. Other
experiments suggested that IRF-1 activation also regulated genes
that directly limit replication of several viruses (encephalomyocar-
ditis (EMCV), NDV, hepatitis C (HCV), yellow fever, Sindbis, and
vesicular stomatitis (VSV) viruses) independently of IFN production
[23,24,25]. In addition to these functions, IRF-1 transduces part of
the IFN-c signal (reviewed in [26]). Consistent with this, EMCV
infection in IRF-1
-/- fibroblasts was associated with a decrease in
IFN-c-stimulated genes [27], and IFN-c-induced upregulation of
cytokines and chemokines in macrophages (Mw) required the
transcriptional activity of IRF-1 [28,29,30,31].
Studies with deficient mice have confirmed an important role
for IRF-1 in controlling infection against EMCV or murine c-
herpesvirus 68 (cHV68) [27,32]. However, IRF-1
-/- mice did not
show defects in the systemic type I IFN response in vivo after NDV
infection [33] suggesting that it might regulate IFN genes in a
pathogen and cell type-dependent manner. Independent of its
possible effects on transducing IFN signals, IRF-1 has been defined
as a tumor suppressor gene [34,35,36] that inhibits cell
proliferation or enhances apoptosis in a manner dependent on
its transcriptional activity (reviewed in [37,38]). IRF-1 also
regulates adaptive immune responses. Naı ¨ve IRF-1
-/- mice exhibit
blunted levels of CD8
+ T cells in peripheral lymphoid organs in
part, due to decreased class I MHC expression and impaired
selection in the thymus [39,40,41]. Moreover, IRF-1
-/- Mw have
decreased IL-12 production during bacterial and parasitic
infection, whereas IRF-1
-/- CD4
+ T cells show reduced IL-12
receptor expression and are prone to TH2 skewing [42,43,44].
Nonetheless, because adoptive transfer of wild type peritoneal
exudates cells restores induction of Th1 cells in IRF-1
-/- mice,
these defects are not entirely T cell intrinsic [45]. Finally, increased
numbers of CD4
+CD25
+FoxP3
+ regulatory T cells were reported
in naı ¨ve IRF-1
-/- mice [46].
Here, we evaluated the function of IRF-1 in the context of
immunity to WNV infection. IRF-1
-/- mice were vulnerable to
WNV infection with enhanced viral replication in peripheral tissues
and subsequent early dissemination to the brain and spinal cord.
Despite a substantial baseline defect in the numbers of naı ¨ve CD8
+
T cells after WNV infection, IRF-1
-/- mice rapidly expanded
antigen-specific IFN-c-producing, granzyme B
+ CD8
+ T cells that
were capable of killing targets and clearing virus from infected
neurons. Although WNV-specific CD8
+ T cells proliferated more
rapidly in IRF-1
-/- mice, they did not ‘‘catch up’’ quickly enough to
mitigate the damage caused by early CNS dissemination that was
due to impaired control of WNV in peripheral tissues.
Results
IRF-1 is required for control of lethal WNV infection
To understand the contribution of IRF-1 in controlling WNV
infection in vivo, wild type and IRF-1
-/- C57BL/6 mice were
infected subcutaneously with 10
2 PFU of a highly pathogenic
WNV strain (New York 2000) and monitored for survival. IRF-1
-/-
mice were more vulnerable to WNV infection, with a 0% survival
rate and a mean time to death of 9.561.1 compared to age-
matched wild type mice, which had a 65% survival rate and a
mean time to death of 10.761.6 (P,0.0001, Fig. 1A).
IRF-1
-/- mice exhibit enhanced WNV replication in
peripheral and central nervous system tissues
To begin to define how an IRF-1 deficiency increased the
susceptibility of mice to WNV infection, we measured viral burden
by fluorogenic quantitative RT-PCR or viral plaque assay at days 1,
2, 4, 6 and 8 post infection in serum, peripheral organs (draining
lymph nodes, spleen and kidney) and the CNS (brain and spinal
cord).
(a) Peripheral tissues. Increased levels of viral RNA were
observed in serum of IRF-1
-/- mice at days 2, 4 and 6 when
compared to wild type mice (4.3-, 21- and 22-fold higher,
respectively, P,0.05) (Fig 1B). Similarly, in the draining lymph
nodes, enhanced WNV replication also was observed at day 3, 4
and 5 after infection (Fig 1C, 6-, 27- and 23-fold reduction,
respectively, P#0.05). Thus, IRF-1 is required to control the early
stages of WNV infection in vivo.
As seen previously [47], infectious WNV was not detected in the
spleen of infected wild type animals until 4 days after infection. In
contrast, 71% (5 of 7) of IRF-1
-/- mice had measurable levels of
WNV at day 2 (mean titer 10
3.1 PFU/g, P,0.0001) (Fig 1D).
Sustained viral replication was still observed at days 6 (9 of 10,
mean titer 10
4.3 PFU/g, P,0.0001) and 8 (8 of 10, 10
3.0 PFU/g,
P,0.0001), time points at which WNV was cleared from the
spleen of wild type mice.
Normally, replication of WNV occurs to low, if at all detectable
levels in the kidneys of adult wild type C57BL/6 mice [6]. In
contrast, WNV infection of the kidney was observed in mice
lacking components of the type I IFN signaling including the IFN-
ab receptor, IRF-3, or IRF-7 [10,15,47]. In the current study,
WNV infection was detected in the kidneys of IRF-1
-/- mice at
days 4 (9 of 10, mean titer 10
3.5 PFU/g, P,0.0001), 6 (10 of 10,
mean titer 10
3.5 PFU/g, P,0.0001) and 8 (5 of 10, mean titer
10
3.3 PFU/g, P,0.05) (Fig 1E). Thus, IRF-1 restricts WNV tissue
tropism and modulates infection in peripheral tissues.
Author Summary
Interferon regulatory factor (IRF)-1 is a transcription factor
that has been implicated in immune regulation and
induction of type I IFN gene expression. To better
understand the contribution of IRF-1 to antiviral immunity,
we infected cells and mice lacking IRF-1 with West Nile
virus (WNV), an encephalitic flavivirus. IRF-1
-/- mice were
uniformly vulnerable to WNV infection with enhanced viral
replication and rapid dissemination into the brain and
spinal cord. Studies in cell culture revealed a cell-type
specific antiviral role as IRF-1
-/- macrophages but not
fibroblasts supported enhanced WNV replication. IRF-1
also had an independent effect on CD8
+ T cell responses.
Although fewer CD8
+ T cells were observed in naı ¨ve
animals, WNV-specific CD8
+ T cells rapidly expanded in IRF-
1
-/- mice and retained the capacity to clear infection.
Collectively, our studies define independent roles for IRF-1
in restricting WNV pathogenesis and modulating the
protective CD8
+ T cell response.
IRF-1 Regulation of Antiviral Immunity
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WNV to the central nervous system (CNS) of IRF-1
-/- mice
occurred more rapidly. Indeed, 100% of IRF-1
-/- mice manifested
WNV infection in the brain at day 4 (mean titer 10
3.7 PFU/g,
P,0.0001),a time at whichnoinfectiousWNVwasdetected inwild
type animals (Fig 1F). Moreover, IRF-1
-/- mice developed higher
viral titers in the brain when compared to wild type animals on days
6 (meantiter 10
5.2 PFU/gvs.10
4.2 PFU/g,P,0.0001) and 8 (mean
titer 10
5.2 PFU/g vs. 10
3.9 PFU/g, P,0.05). Similarly, early
infection of the spinal cord was observed in IRF-1
-/- mice with
20% (2 of 10) and 90% (9 of 10) having detectable viral loads at day
4 (10
3.1 PFU/g)and atday6 (10
4.9 PFU/g,P,0.0001),respectively
(Fig 1G), whereas infection in wild type mice was not observed at
these times. Higher titers in IRF-1
-/- mice were also observed at day
8 (mean titer 10
5.5 PFU/g vs. 10
3.4 PFU/g, P,0.0001).
Collectively, these data show that an absence of IRF-1 resulted in
early spread and sustained WNV replication in CNS tissues.
An absence of IRF-1 does not alter type I IFN levels in the
draining lymph node or serum
Because of the early viral phenotype in peripheral tissues, and
prior results with other viruses implicating IRF-1 as an activator of
IFN-ab gene transcription in cell culture [20,21,22], we
hypothesized that IRF-1 might contribute to induction of type I
IFN responses locally in specific tissues or compartments. To test
this, we measured levels of IFN-a and b mRNAs in the draining
lymph nodes of WNV-infected mice at day 2 after infection. In
wild type and IRF-1
-/- mice, the induction of the IFN-a/b genes
was comparable as both showed increased levels of IFN-a and b
mRNA after WNV infection (,10 to 20 fold increase for IFN-a
and IFN-b)( Fig 2A). We also observed no statistically significant
difference in induction of SOCS-1 and SOCS-3 in the draining
lymph node, genes that are induced by IFN-c [48].
Although IRF-3 and IRF-7 jointly regulate the induction of
systemic IFN-ab after WNV infection, their combined deficiency
Figure 1. Survival and virologic analysis for wild type and IRF-1
-/- C57BL/6 mice. (A) Eight to twelve week old mice were inoculated with
10
2 PFU of WNV by footpad injection and followed for mortality for 21 days. Survival differences were statistically significant (n=24, IRF-1
-/-; n=20,
wild type mice; P,0.0001). B-G. Viral burden in peripheral and CNS tissues after WNV infection. WNV RNA in (B) serum and (C) draining lymph node,
and infectious virus in the (D) spleen, (E) kidney, (F) brain, and (G) spinal cord were determined from samples harvested on days 1,2, 3, 4, 5, 6, and 8
using qRT-PCR (B and C) or viral plaque assay (D-G) as indicated. Data are shown as viral RNA equivalents or PFU per gram of tissue for 7 to 10 mice
per time point. For all viral load data, the solid line represents the median PFU per gram at the indicated time point, and the dotted line represents
the limit of sensitivity of the assay. Error bars indicate the standard deviations (SD). Asterisks indicate values that are statistically significant (*, P,0.05;
***, P,0.0001) compared to wild type mice.
doi:10.1371/journal.ppat.1002230.g001
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hypothesized that IRF-1 might contribute to the systemic levels of
IFN-ab in circulation after infection. Mice were infected with
WNV and the presence of biologically active IFN in serum was
monitored using a previously validated EMCV-L929 cell bioassay
[47,49]. Type I IFN activity in the serum of infected wild type
mice peaked at day 3 and then decreased by day 5 (Fig 2B). IFN
activity in the WNV-infected IRF-1
-/- mice was equivalent or
greater than that observed in wild type mice. For example, 5 to 10-
fold higher levels of type I IFN activity were observed in IRF-1
-/-
mice at day 3 after infection (P,0.001). Thus, a deficiency of IRF-
1 in vivo did not diminish early type I IFN levels in lymphoid
tissues or circulation after WNV infection; these results are
consistent with that observed previously after NDV infection [33].
IRF-1 restricts WNV replication in macrophages but does
not affect IFN-ab induction
To better understand the viral replication phenotype of IRF-1
-/-
mice, we investigated how an absence of IRF-1 affects WNV
infection of primary mouse embryonic fibroblasts (MEF) and Mw.
While Mw are physiologic targets of WNV infection in vivo
[6,50,51], we used MEFs as a comparison cell type because
historically they have been used to study the significance of IRF in
regulating cellular antiviral immune responses [3,19,52]. Multi-
step viral growth curves performed in wild type and IRF-1
-/- MEF
showed no significant differences in WNV replication at any of the
time points tested (P . 0.2) (Fig 3A). However, increased
replication was observed at 48 and 72 hours after infection in IRF-
1
-/- Mw when compared to wild type cells (Fig 3B, 2.5-fold,
P=0.02 and 7.4-fold, P=0.001, respectively). Earlier studies
showed that a defect in type I IFN signaling enhanced WNV
infection of primary Mw [15] while recent work indicated that
IRF-3 and IRF-7 only partially regulated IFN-b induction after
WNV infection in Mw [19]. To define a possible role for IRF-1 in
modulating IFN gene induction, cells were infected with WNV
and levels of IFN-a and b mRNA were measured by qRT-PCR.
Notably, levels of IFN-a and IFN-b were significantly higher at
48 hours in IRF-1
-/- Mw (Fig 3D and F); the increased levels were
likely a consequence of greater viral replication, analogous to that
seen in MyD88
-/- Mw [53]. Consistent with this, IFN-ab gene
induction was not altered in IRF-1
-/- MEF (Fig 3C and E). Thus,
a deficiency in IRF-1 enhanced viral growth in Mw yet this was
not associated with a defect in the type I IFN response.
IRF-1 mediates IFN-c but not IFN-b-dependent antiviral
effects in macrophages
Since previous studies have defined a role of IRF-1 in mediating
the antiviral effects of IFN-c signaling [54], we evaluated the
contribution of IRF-1 to the antiviral effects of either IFN-b or
IFN-c in Mw after WNV infection. We pretreated wild type and
IRF-1
-/- Mw with increasing concentrations of either IFN-b or
IFN-c, infected with WNV, and measured viral burden.
Pretreatment with increasing amounts of IFN-b inhibited WNV
replication in both wild type and IRF-1
-/- Mw (2-, 66- and 104-fold
inhibition versus 1.6-, 20- and 193-fold inhibition, respectively,
P.0.3 at 1, 10 and 100 IU/ml) (Fig 4A). Whereas pretreatment
with IFN-c significantly decreased viral infection in wild type Mw,
it had virtually no inhibitory effect in IRF-1
-/- cells (3.3-, 34- and
116-fold inhibition in wild type cells versus 1.3-, 1.6- and 2.9-fold
inhibition in IRF-1
-/- cells, P,0.05 at 1, 10 and 100 IU/ml)
(Fig 4B). Thus, in Mw, IRF-1 is required to mediate the inhibitory
effect of IFN-c but dispensable for the antiviral activity of IFN-b
against WNV infection.
To determine whether the increased WNV replication in IRF-
1
-/- Mw was associated with a paracrine antiviral effect of IFN-c,
we performed depletion experiments with a neutralizing anti-
mouse IFN-c monoclonal antibody (MAb H22) [55]. To confirm
the neutralizing capacity of the H22 MAb, wild type Mw were
pretreated with increasing amounts of IFN-c that was pre-mixed
with either H22 or an isotype control MAb, and then infected with
WNV; at 48 hours, viral burden was quantified by plaque assay.
Pre-incubation of IFN-c with the isotype control MAb resulted in
a dose-dependent inhibition in WNV infection (Fig 4C). Since
these controls confirmed that H22 MAb neutralized the IFN-c-
dependent antiviral activity against WNV, we performed multi-
step viral growth in wild type and IRF-1
-/- Mw in the presence of
H22 or the isotype control MAb, each in the absence of exogenous
IFN-c. Notably, WNV replication in the presence of the isotype
control MAb gradually increased in both wild type and IRF-1
-/-
Mw (Fig 4D and 4E) and exhibited growth kinetics virtually
identical to that observed in the absence of MAb (see Fig 3B).
Similar results were obtained on WNV growth in the presence of
H22. These results imply that WNV-infected Mw did not produce
sufficient IFN-c to explain the difference in viral growth between
wild type and IRF-1
-/- cells. Thus, although IRF-1 is essential for
Figure 2. IFN-dependent responses in lymph node and serum
of wild type and IRF-1
-/- mice infected with WNV. A. Mice were
inoculated with 10
2 PFU of WNV by footpad injection and sacrificed at 2
days post infection. After harvesting of the draining inguinal lymph
node, IFN-a, IFN-b, SOCS-1, and SOCS-3 mRNA levels were measured by
quantitative RT-PCR and compared to mock-infected animals. B. Type I
IFN levels were determined from serum collected on days 1 through 5
after WNV infection of wild type or IRF-1
-/- mice by an EMCV bioassay in
L929 cells. Data reflect averages of serum samples from 3 to 7 mice per
time point and the data are expressed as international units (IU) of type
I IFN per ml. The specificity of the assay was confirmed with an anti-IFN-
abR neutralizing antibody (data not shown). Asterisks indicate values
that are statistically significant (***, P,0.001; *, P,0.05).
doi:10.1371/journal.ppat.1002230.g002
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cell-intrinsic difference in replication in IRF-1
-/- cells must occur
independently of the IFN-c response.
WNV-specific B cell responses remain intact in IRF-1
-/-
mice
Innate immune signaling can modulate the induction and
quality of antigen-specific antibody responses after viral infection
[18,56]. As a depressed antiviral antibody response can promote
increased viremia and early dissemination of WNV [57], we
evaluated whether a deficiency of IRF-1 modulated humoral
immune responses. Notably, similar or higher levels of WNV-
specific IgM and IgG were detected in IRF-1
-/- mice at days 5 and
8 after infection, and no difference in neutralization titer was
observed (Fig 5). Thus, the virologic phenotype observed in IRF-
1
-/- mice likely was not due to a primary defect in B cell function.
WNV-specific CD8
+ T cell responses are hyperactive in
IRF-1
-/- mice
Naı ¨ve IRF-1
-/- mice have quantitative defects in the number of
CD8
+ T cells in peripheral lymphoid organs because of impaired
negative and positive selection in the thymus [39,40,41].
Moreover, IRF-1
-/- mice also have defects in TH1 responses due
to altered production of IL-12 by Mw and hypo-responsiveness of
T cells to the effects of IL-12 during bacterial and parasite
infections [42,43,44]. Because WNV is controlled in part, by
Figure 3. IRF-1 modulates WNV infection in primary Mw but not in MEF. A-B. MEF (A)o rM w (B) generated from wild type or IRF-1
-/- mice
were infected, and virus production was evaluated at the indicated times post infection by plaque assay. Values are an average of quadruplicate
samples generated from at least three independent experiments, error bars represent the SD, and asterisks indicate differences that are statistically
significant relative to wild type mice (*, P,0.05; **, P,0.005). C-F. The induction of IFN-a (C-D) or IFN-b (E-F) mRNA in WNV-infected MEF (C, E)o r
Mw (D, F) was analyzed by qRT-PCR. The data are the average of at least three independent experiments performed in triplicate, error bars represent
the SD, and asterisks indicate differences that are statistically significant relative to wild type mice (*, P,0.05).
doi:10.1371/journal.ppat.1002230.g003
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+ T cells that clear infection
from peripheral and CNS tissues [58,59,60,61,62], we evaluated
whether the severe clinical phenotype after infection in IRF-1
-/-
mice was explained in part, by a failure of antigen-specific cells to
expand and migrate to infected tissues. Initial studies confirmed a
reduced percentage (,5-fold, P,0.001) and number (,25-fold,
P,0.001) of CD8
+ T cells in the spleens of naı ¨ve IRF-1
-/- mice
(Fig 6A and B). In comparison, the percentage and absolute
number of CD4
+ T cells were largely intact in naive IRF-1
-/- mice.
However, within eight days of WNV infection, the total CD8
+ T
cell population expanded in IRF-1
-/- mice, such that there was a
smaller difference in percentage (,3-fold) and number (,10-fold)
compared to wild type mice (Fig 6C and D). Remarkably, ,60%
of splenic CD8
+ T cells taken directly from WNV-infected IRF-1
-/-
mice expressed high levels of granzyme B (GrB), establishing the
presence of a large pool of potentially cytolytic CD8
+ T cells
(Fig 6E, F, and K); the majority of these GrB
+ CD8
+ T cells were
specific for one D
b-restricted immunodominant epitope on the
WNV NS4b protein (Fig 6I and J, and Fig S1). In comparison,
,0.2% of CD8
+ T cells expressed GrB in naı ¨ve IRF-1
-/- mice
(data not shown). Consistent with this, a significantly higher
percentage (,30% compared to ,5% for wild type, P=0.001) of
IRF-1
-/- CD8
+ T cells produced IFN-c in response to WNV NS4b
peptide restimulation ex vivo (Fig 6G, H, and K). This result was
not specific to the NS4b epitope as similar results were observed
after re-stimulation with an E protein-derived peptide (E771:
IALTFLAV) that comprises a subdominant K
b-restricted T cell
epitope (data not shown). In comparison, neither wild type nor
IRF-1
-/- CD8
+ T cells from WNV-infected mice produced IFN-c
in the absence NS4b or E peptide restimulation (0.1 to 0.2% IFN-
c
+ CD8
+ positive cells from wild type and IRF-1
-/- mice,
respectively). Overall, in the context of WNV infection, IRF-1
-/-
mice paradoxically had more robust antigen-specific T cell
responses.
Mechanism of selective expansion of IRF-1
-/- CD8
+ T cells
The rapid and antigen-specific expansion of CD8
+ T cells in
IRF-1
-/- mice after WNV infection was surprising, given the
previously described defects in negative and positive T cell
selection in the thymus and IL-12 responsiveness in the periphery.
We hypothesized that one of several mechanisms could explain
this phenomenon: (a) WNV-specific IRF-1
-/- CD8
+ T cells were
inherently of higher affinity because they had been selected on
IRF-1
-/- stromal cells expressing lower levels of class I MHC
molecules [39]; (b) IRF-1 directly or indirectly modulated the
numbers of CD4
+CD25
+FoxP3
+ regulatory T cells (Treg) after
WNV infection. A decrease in Treg numbers was recently shown
to cause an increase in numbers of WNV-specific CD8
+ T cells
[63]; or (c) IRF-1 regulated the threshold for activation-induced
proliferation after antigen recognition, consistent with its tumor
suppressor properties. We tested these three hypotheses in the
following ways. To evaluate whether WNV-specific IRF-1
-/- CD8
+
T cells were of higher affinity than wild type CD8
+ T cells, ex vivo
restimulation was performed over a wide range of NS4b peptide
concentrations. Notably, no difference was observed in the
concentration of peptide or the time required for activation of
CD8
+ T cells and expression of IFN-c (Fig 7A and B). Moreover,
we observed a slightly (2.4-fold, P=0.004) decreased number of
CD4
+CD25
+FoxP3
+ Tregs in the spleens of WNV-infected IRF-
1
-/- mice, which could contribute to the skewing of the CD8
+ T
cell response (Fig 7C). However, this reduction is an unlikely
explanation because the CD8
+ T cell response disparity in IRF-1
-/-
Figure 4. The relationship between IFN-c and IRF-1 in Mw. A-B. The antiviral effects of exogenous IFN-b or IFN-c in Mw. Wild type or IRF-1
-/-
Mw were pretreated overnight with the indicated amount of (A) IFN-b (1 to 100 IU/ml) or (B) IFN-c (1 to 100 IU/ml). Subsequently, cells were infected
with WNV at an MOI of 0.01 and one-day later supernatants were harvested and titrated for viral infection. The data are expressed as the log10 fold
inhibition relative to the no IFN treatment control. Asterisks indicate differences that are statistically significant (*, P,0.05). C-E. The antiviral effect of
IRF-1 in macrophages is independent of IFN-c expression. C. The H22 MAb efficiently neutralizes the antiviral effect of exogenous IFN-c treatment.
Mw were pretreated with the indicated concentrations of IFN-c in the presence of H22 anti-IFN-c or an isotype control MAb. Subsequently, cells were
infected with WNV at an MOI of 0.01 and one-day later supernatants were harvested and titrated for viral infection. The data are expressed as the
log10 fold inhibition relative to the no IFN treatment control. (D) Wild type or (E) IRF-1
-/- Mw were infected at an MOI of 0.01 in the presence of H22
anti-IFN-c or an isotype control MAb. Virus production was evaluated at the indicated times by plaque assay. Values are an average of triplicate
samples generated from three independent experiments, and error bars represent the SD. Differences were not statistically significant.
doi:10.1371/journal.ppat.1002230.g004
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-/- mice, which
entirely lack Tregs [63].
Cell-intrinsic and –extrinsic defects of IRF-1 alter CD8
+ T
cell expansion
To assess how IRF-1 regulates the rapid expansion of CD8
+
T cells after WNV infection, we performed competitive adoptive
transfer experiments with wild type (CD45.1) and IRF-1
-/-
(CD45.2) CD8
+ T cells into IRF-1
+/+ RAG1
-/- mice. Within
12 hours of transfer, slightly greater numbers (,1.8-fold) of wild
type (CD45.1) CD8
+ T cells were observed in recipient RAG1
-/-
mice (data not shown). Animals subsequently were infected with
WNV and harvested 8 days later for profiling of CD8
+ T cells.
Notably, we observed a cell-intrinsic effect of IRF-1 on the
proliferative potential of CD8
+ T cells as the wild type (CD45.1)
cells rapidly expanded compared to IRF-1
-/- (CD45.2) counter-
parts (4.1 and 4.4-fold increase in percentage and number,
respectively, P#0.02; Fig 8A). Consistent with this, although
the percentage of NS4b-specific IFN-c
+ or GrB
+ CD8
+ Tc e l l s
was equivalent (P . 0.6) in both the wild type (CD45.1) and
IRF-1
-/- (CD45.2) compartments (Fig 8B), the total number of
IRF-1
-/- (CD45.2) trended lower (3.5-fold lower for IFN-c
+
(P=0.09) and 4.7-fold lower for GrB
+ cells (P=0.03)). Thus,
CD8
+ T cells lacking IRF-1 are at a competitive disadvantage
compared to wild type cells within an IRF-1
+/+ stromal
environment.
To determine whether an IRF-1 environment contributes to
shaping the antigen-specific CD8
+ T cell responses after WNV
infection, we adoptively transferred wild type (CD45.1) CD8
+ T
cells into IRF-1
-/- (CD45.2) or wild type (CD45.2) mice, and
compared antigen-specific responses of the donor and host CD8
+
T cells (Fig 8C). Remarkably, CD45.1 wild type CD8
+ T cells in
an IRF-1
-/- mouse generated a larger WNV antigen-specific
population compared to those observed in wild type mice (Fig 8D
and E). These values approached but did not attain those
observed with unperturbed, WNV-infected IRF-1
-/- mice. These
observations suggest that IRF-1 expression outside of the T cell
compartment also regulates the magnitude of the antigen-specific
CD8
+ T cell response during WNV infection.
To further understand the rapid expansion of antigen-specific
CD8
+ Tc e l l si nIRF-1
-/- mice, we evaluated the percentage and
number of cells that were proliferating at the peak of the
response, based upon the expression of Ki67, a protein
upregulated during the cell cycle. Ki67 expression was evaluated
directly ex vivo, without peptide restimulation, in splenocytes of
IRF-1
-/- and wild type mice at 8 days after WNV infection. A
significantly higher percentage (66 versus 10% P,0.008) and
number (17610
4 versus 1.8610
4 cells, P,0.008) of WNV-
specific CD8
+ Tc e l l si nIRF-1
-/- mice were proliferating at day 8
(Fig 9A). To address why there was an increase in proliferation
Figure 5. Antibody responses in IRF-1
-/- mice remain intact after
WNV infection. A-B. Wild type and IRF-1
-/- mice were inoculated with
10
2 PFU of WNV-NY by footpad injection and serum samples collected
on days 5 and 8 after subcutaneous WNV infection were assayed by
ELISA for WNV-E specific (A) IgM and (B) IgG. Titers are expressed as a
scatter plot of the reciprocal serum dilution that was three standard
deviations above background (endpoint titer). All IgM and IgG titers
were not statistically significant from wild type mice (P . 0.1). C.
Neutralizing antibody titers in wild type and IRF-1
-/- mice from serum
collected at day 8 after infection. Filled circles reflect samples from
individual mice and reflect the serum dilution that inhibits 50% of
infection of Vero cells as judged by a focus reduction neutralization
assay. No statistical difference (P . 0.3) was observed.
doi:10.1371/journal.ppat.1002230.g005
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+ Tc e l l si nIRF-1
-/- mice during WNV
infection, CD8
+ T cells were isolated (,90% purity) by negative
selection, labeled with carboxyfluorescein diacetate, and stimu-
lated with plate-bound anti-CD3e and anti-CD28 in vitro.
Notably, IRF-1
-/- CD8
+ T cells proliferated more rapidly than
wild type cells at both 48 and 72 hours after stimulation (Fig 9B).
Collectively, these results confirm that IRF-1
-/- CD8 T cells have
an intrinsic capacity to proliferate more rapidly in the context of
stimulation through the T cell receptor, suggesting that IRF-1
acts to regulate T cell proliferation.
Consequences of CD8
+ T cell expansion in IRF-1
-/- mice
The accumulation of CD8
+ T cells in the brain can be
protective in the context of WNV infection depending on the
numbers of migrating cells, the extent of neuronal infection, the
timing of trafficking, and the inherent virulence of the viral strain
[58,60,61,64]. To assess whether the increase in relative numbers
of WNV-specific CD8
+ T cells in the spleen of IRF-1
-/- mice was
also observed in the CNS, we evaluated leukocyte accumulation in
the brain. Leukocytes were recovered from the brains of wild type
and IRF-1
-/- mice at day 8 post-infection after perfusion.
Figure 6. Splenic T cell responses in IRF-1
-/- mice. A-B. The total percentage (A) and number (B) of CD4
+ and CD8
+ T cells were obtained from
naı ¨ve mice and determined by flow cytometry. A scatterplot of the data is shown and was generated from three to six wild type or IRF-1
-/- mice. The
bar indicates average values and asterisks denote differences that are statistically significant (P,0.05). C-H Wild type and IRF-1
-/- mice were
inoculated with 10
2 PFU of WNV by footpad injection and spleens were harvested on day 8. C-D. The total percentage (C) and number (D) of CD8
+ T
cells were determined by flow cytometry. A scatterplot of the data is shown and was generated from 12 to 14 wild type or IRF-1
-/- mice. The bar
indicates average values and asterisks denote differences that are statistically significant (P,0.05). E-F. The total percentage (E) and number (F)o f
splenic CD8
+ T cells expressing GrB. Cells were harvested directly from dissected spleens and analyzed by flow cytometry (K, top dot plots). A
scatterplot of the data is shown and was generated from 12 to 14 wild type or IRF-1
-/- mice. The bar indicates average values and asterisks denote
differences that are statistically significant (P,0.05). G-H. Splenocytes were stimulated ex vivo with D
b-restricted NS4b peptide, stained for CD3 and
CD8b, and intracellular IFN-c, and analyzed by flow cytometry. The primary data is shown as dot plots of gated CD3
+CD8
+ cells (K, bottom dot plot)
and (G) a summary of the percentage and (H) total number of CD3
+CD8
+ T cells positive for intracellular IFN-c after peptide restimulation. A
scatterplot of the data is shown and was generated from 12 to 14 wild type or IRF-1
-/- mice. Note, the data in panel G is presented with the
background IFN-c staining subtracted: wild type CD8
+ IFN-c
+ background of 0.1% (n=14 mice) and IRF-1
-/- CD8
+ IFN-c
+ background of 0.2% (n=12).
The bar indicates average values and asterisks denote differences that are statistically significant (P,0.05). I-J. The total percentage (I) and number (J)
of splenic CD8
+ T cells co-expressing GrB and D
b-NS4b peptide as judged by tetramer staining and flow cytometry. A scatterplot of the data from
three independent experiments is shown and was generated from 9 to 10 wild type or IRF-1
-/- mice. The bar indicates average values and asterisks
denote differences that are statistically significant (P,0.05).
doi:10.1371/journal.ppat.1002230.g006
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high/CD11b
high
Mw, CD45
low/CD11b
high activated microglia, and CD4
+ T cells
were observed in the brains of WNV-infected wild type and IRF-
1
-/- mice (data not shown). In comparison, higher percentages
(.2-fold) and total numbers (,4-fold) of D
b-restricted NS4b
tetramer
+ CD3
+ CD8
+ T cells were detected in the brains of IRF-
1
-/- mice (P,0.002) (Fig 10A-C). Thus, a deficiency of IRF-1
enhanced accumulation of antigen-specific CD8
+ T cells in the
brains of WNV-infected mice.
To determine the potential significance of the increased
numbers of IRF-1
-/- CD8
+ T cells, we assessed their functional
activity in vivo and ex vivo. When NS4b-peptide pulsed naı ¨ve
splenocytes were adoptively transferred into WNV-infected wild
type or IRF-1
-/- mice, IRF-1
-/- CD8
+ T cells showed an equivalent
if not slightly greater capacity to lyse target cells (98% versus 80%,
P,0.03; Fig 10D). Importantly, NS4b-pulsed targets were not
lysed when transferred into naı ¨ve wild type or IRF-1
-/- mice. We
next performed adoptive transfer studies with WNV-primed wild
type or IRF-1
-/- CD8
+ T cells. To generate WNV-primed CD8
+ T
cells, wild type or IRF-1
-/- mice were infected with WNV, and on
day 7, spleens were harvested and 2610
5 NS4b tetramer
+ CD8
+ T
cells were adoptively transferred into congenic five week-old wild
type mice two days after WNV infection, and 4 days later (day 6
after infection), brains were harvested to evaluate the effect on
control of WNV infection. While addition of naı ¨ve CD8
+ T cells
did not affect viral burden in the brain [60], wild type and IRF-1
-/-
CD8
+ T cells both reduced viral titers (Fig 10E,P ,0.02). To
directly establish that IRF-1
-/- CD8
+ T cells could clear WNV
from neurons, we used an ex vivo viral clearance assay with
primary neurons derived from the cerebral cortex of wild type
C57BL/6 mouse embryos [60]. One hour after infection, WNV-
primed wild type or IRF-1
-/- CD8
+ T cells were added at an
effector to target (E:T) ratio of ten to one. At 48 hours after
infection, the level of infectious WNV in the neuronal supernatants
was measured by focus-forming assay. Addition of naı ¨ve CD8
+ T
cells does not reduce WNV infection in neurons [60]. In
comparison WNV-primed CD8
+ T cells significantly reduced
(,40 to 1400-fold, P,0.006) infectious virus production from
infected cortical neurons, with an even greater (35-fold, P,0.02)
inhibitory effect seen with IRF-1
-/- compared to wild type CD8
+ T
cells (Fig 10F). Collectively, these experiments suggest that WNV-
primed IRF-1
-/- CD8
+ T cells are capable of controlling neuronal
infection. However, this response is not sufficient to compensate
for increased viral replication in peripheral tissues, which results in
early and enhanced infection in the CNS of IRF-1
-/- mice.
Discussion
In this study, we identified IRF-1 as an essential regulator of the
host immune response against WNV infection, and show that it
governs processes of both the innate and adaptive immune
responses that control outcome. IRF-1
-/- mice were vulnerable to
lethal infection with enhanced viremia, increased viral replication
in peripheral tissues, altered tropism, and rapid dissemination into
the CNS. Ex vivo analysis showed a cell-specific utilization of IRF-
1 in controlling WNV replication. Although an absence of IRF-1
did not alter WNV infection in MEF, IRF-1
-/- Mw supported
enhanced viral replication. Additionally, we identified a surprising
phenotype with respect to the effects of IRF-1 on the induction of
WNV-specific CD8
+ T cells. Despite markedly fewer CD8
+ T cells
in naı ¨ve IRF-1
-/- mice at baseline, we observed a rapid expansion
in the periphery of antigen-specific CD8
+ T cells that were IFN-c
+
and GrB
+, which was associated with increased accumulation in
the brain. Although IRF-1
-/- CD8
+ T cells expanded rapidly and
were capable of killing targets and efficiently clearing virus from
infected neurons, they did not attain sufficient numbers quickly
enough to mitigate the increased infection in the CNS caused by
the compromised early innate control of WNV in peripheral
tissues.
Innate immunity and particularly type I (IFN-ab), II (IFN-c)
and III (IFN-l) IFN responses orchestrate control of infection by
many DNA and RNA viruses [65,66,67]. Analogously, IFN-abR
-/-
[15], IFN-c
-/- or IFN-cR
-/- [68,69], and IFN-lR
-/- (IL28A) (H. M.
Lazear and M. Diamond, unpublished results) mice all show
enhanced susceptibility to WNV infection. The phenotype
observed in the IRF-1
-/- mice with WNV infection was in some
ways similar to primary defects in IFN responses: increased
replication in peripheral tissues at early time points that was
Figure 7. Mechanism of selective expansion of WNV-specific CD8
+ T cells in IRF-1
-/- mice. A. Assessment of CD8
+ T cell avidity. Ex vivo
restimulation of CD8
+ T cells from wild type or IRF-1
-/- mice was performed over the indicated range of NS4b peptide concentrations. Cells were
stained for CD3, CD8b, and intracellular IFN-c, and analyzed by flow cytometry. The data are normalized relative to the peak percentage of cells
expressing IFN-c (for wild type (,5%) or IRF-1
-/- (,30%)) after incubation with NS4b peptide (10
-7 M). Data were generated from two independent
experiments with 6 to 8 wild type or IRF-1
-/- mice in total. B. Kinetics of CD8
+ T cell induction. Wild type or IRF-1
-/- CD8
+ T cells from WNV-infected
mice were harvested at day 8 and restimulated ex vivo with NS4b peptide (10
-7 M) for the indicated times. Cells were stained for CD3, CD8b, and
intracellular IFN-c, and analyzed by flow cytometry. The data are normalized relative to the peak percentage of cells expressing IFN-c (for wild type
(,5%) or IRF-1
-/- (30%) after incubation with NS4b peptide (6 hour time point). Data were generated two independent experiments with 6 to 8 wild
type or IRF-1
-/- mice in total. C. Treg analysis in WNV-infected wild type or IRF-1
-/- mice. At day 8, spleens were harvested and analyzed for the number
of Treg using antibodies to CD4, CD25, and FoxP3. Data are displayed as a scatterplot and reflect six individual wild type or IRF-1
-/- mice from two
independent experiments. Asterisks indicate values that are statistically different.
doi:10.1371/journal.ppat.1002230.g007
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Because IRF-1 is important for efficient transduction of the
antiviral signals downstream of IFN-c [27], the early virologic
phenotype in WNV-infected IRF-1
-/- mice might be expected to
phenocopy IFN-c
-/- mice [68,69]. However, a comparison of the
current data with published results revealed a more severe
phenotype in IRF-1
-/- mice, with higher and sustained infection
in the spleen, altered tissue tropism with infection in the kidney,
and higher titers in the brain and spinal cords between days 4 and
8. Thus, IFN-c-independent immune regulatory functions must
Figure 8. Adoptive transfer experiments identify cell-intrinsic and cell-extrinsic effects of IRF-1 on CD8
+ T cell expansion. A-B. Equal
numbers of naı ¨ve donor splenic CD8
+ T cells from wild type SJL (CD45.1) or IRF-1
-/- (CD45.2) mice were harvested, purified by negative selection, and
transferred (2610
6 cells) into recipient IRF-1
+/+ RAG1
-/- congenic mice. Mice were infected with WNV and eight days later, (A) splenocytes were
harvested, and the number and percentage of CD45.1
+ and CD45.2
+ CD8
+ T cells were enumerated. (B) Splenocytes were stimulated ex vivo with D
b-
restricted NS4B peptide, stained for CD3 and CD8b, and intracellularly for IFN-c and GrB, and analyzed by flow cytometry. Results are the average of
experiments with five mice. C-E. Naı ¨ve donor splenic CD8
+ T cells from wild type SJL (CD45.1) mice were harvested, purified by negative selection,
and transferred (1610
6 cells) into recipient CD45.2
+ IRF-1
-/- mice. Animals were infected with WNV and eight days later, splenocytes were harvested.
(C) Flow cytometry dot plots showing percentage of donor (SJL (CD45.1)) and host (CD45.2
+ IRF-1
-/-) CD8
+ T cells that are positive for GrB or IFN-c
after ex vivo peptide restimulation. D-E. Graphical summary of the percentage and total number of IFN-c
+ or GrB
+ SJL (CD45.1) CD8
+ T cells after
transfer into CD45.2
+ IRF-1
-/- mice and ex vivo peptide stimulation. A scatterplot of the data is shown and was generated from 5 wild type or IRF-1
-/-
mice. Note, the percentage and total number of IFN-c
+ or GrB
+ wild type and IRF-1
-/- CD8
+ T cells in unperturbed yet WNV-infected mice are shown
for comparison, some of which were performed in parallel. The bar indicates average values and asterisks denote differences that are statistically
significant (P,0.05).
doi:10.1371/journal.ppat.1002230.g008
Figure 9. Proliferative capacity of IRF-1
-/- CD8
+ T cells. A. Assessment of CD8
+ T cell proliferative capacity at day 8 after WNV infection. CD8
+ T
cells from wild type or IRF-1
-/- mice were stained for CD8b, intracellular GrB and intranuclear Ki-67, and analyzed by flow cytometry. Representative
flow cytometry dot plots gated on CD8b
+ cells, showing the percentage of antigen-specific proliferating CD8b
+GrB
+Ki-67
+ cells. Graphical summary of
the percentage and total number of CD8b
+GrB
+Ki-67
+ T cells. A scatterplot of the data is shown and was generated from two independent
experiments with 5 wild type or IRF-1
-/- mice. B. In vitro proliferative capacity of purified naı ¨ve CD8
+ T cells. Representative flow cytometry profiles of
carboxyfluorescein diacetate dilution from CD8b
+ T cells stimulated with plate bound anti-CD3e (1 mM) and anti-CD28 (1 mM) at three time points.
The data are representative of one individual mouse per group and the experiment was repeated three independent times with two mice per group
each time.
doi:10.1371/journal.ppat.1002230.g009
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-/- compared to IFN-c
-/-
mice.
IRF-1 is not required for induction of the IFN-ab genes in MEF
and Mw in response to WNV infection, results that agree with
experiments with NDV-infected fibroblasts [33,40] or reovirus-
infected myocytes [70]. Instead, IRF-3 and IRF-7 appear as the
primary IRF transcriptional activators downstream of RIG-I and
MDA5 recognition and IPS-1 signaling for efficient IFN-ab gene
induction after WNV infection of MEF and Mw [18,19]. The
antiviral effect of IRF-1 was cell type-specific as enhanced WNV
replication was observed preferentially in Mw. An IRF-1-
dependent antiviral signature is consistent with recent ectopic
expression studies in human cells, which showed broad antiviral
activity of IRF-1 against a range of viruses [25]. At present, we do
Figure 10. CD8
+ T cell accumulation in the CNS of IRF-1
-/- mice after WNV infection. Wild type and IRF-1
-/- mice were inoculated with 10
2
PFU of WNV by footpad injection, brains were harvested on day 8, and leukocytes were isolated after percoll gradient centrifugation. A-B The
percentage and number of WNV-specific (Db-NS4b peptide tetramer
+) CD8
+ T cells was evaluated. The data are an average of experiments from 6
wild type and 5 IRF-1
-/- mice. Asterisks indicate differences that are statistically significant. C. Representative flow cytometry profiles are shown of CD8
and WNV-specific tetramer staining of brain leukocytes from wild type and IRF-1
-/- mice. D. In vivo cytolysis assay. At day 8 after infection, CFDA-
labeled peptide-pulsed CD45.1 naive target cells (splenocytes from B6.SJL mice) were transferred to wild type or IRF-1
-/- (CD45.2) WNV-infected or
naı ¨ve mice (n=6 to 12 per group from two independent experiments), and six hours later, mice were sacrificed and splenocytes analyzed for the ratio
of peptide pulsed to non-pulsed cells by interrogating cells in the CD45.1 gate. The percentage of target cell killing in vivo was calculated by
determining the ratio of peptide-pulsed versus unpulsed cells for each mouse, and by normalizing to that seen in naive mice. E. WNV titers from the
brains (day 6 post infection) of wild type mice after adoptive transfer of wild type or IRF-1
-/- WNV primed NS4b-specific CD8
+ T cells (2610
5). CD8
+ T
cells were purified by negative selection and transferred 48 hours after infection. The data are an average of experiments from 6 to 9 recipient mice.
Asterisks indicate differences that are statistically significant. F. CD8
+ T cell-mediated control of WNV infection in cortical neurons. Cortical neurons
from embryonic wild type mice were dissected and cultured. After infection with WNV at an MOI of 0.001 for one hour and extensive washing,
positively-selected WNV-primed CD8
+ T cells from wild type or IRF-1
-/- mice were added at a 10:1 E:T ratio. Supernatants were harvested 48 hours
later and the viral titer was measured by focus forming assay. Asterisks indicate differences that are statistically significant.
doi:10.1371/journal.ppat.1002230.g010
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contribute directly to the virologic phenotype in IRF-1
-/- Mw.
Comparative microarray analysis of WNV-infected wild type and
IRF-1
-/- MEF and Mw is planned to define a set of uniquely
induced genes that could function to limit WNV infection in a cell-
type specific manner.
Previous studies have reported deficits in T cell function in IRF-
1
-/- mice including low levels of CD8
+ T cells in peripheral
lymphoid tissue [39,40,41]. Based on this, we expected a blunted
and dysfunctional CD8
+ T cell response after WNV infection in
IRF-1
-/- mice; as antigen-specific CD8
+ T cells contribute to
clearance of WNV-infected neurons [58,59,60,61,62,71], we
anticipated uncontrolled viral replication in the brain prior to
death of the animals. Although we confirmed lower levels of
peripheral CD8
+ T cells in naı ¨ve IRF-1
-/- mice, surprisingly, we
observed rapid proliferation of antigen-specific CD8
+ T cells such
that a high fraction (,30%) of CD8
+ T cells in the spleen were
directed against a single viral peptide epitope. Moreover, IRF-1
-/-
CD8
+ T cells were fully capable of lysing target cells and clearing
viral infection from neurons and the brain. This activity was
consistent with a flattening of viral growth kinetics in the brain and
spinal cord between day 6 and 8 in IRF-1
-/- mice. In comparison,
mice with targeted deletions in CD8
+ T cells [58] or perforin [60]
show logarithmic increases in CNS viral burden at this phase of
infection.
How does IRF-1 regulate CD8
+ T cell responses after WNV
infection? Consistent with earlier studies, we observed a CD8
+ T
cell-intrinsic defect in proliferation and/or survival in vivo. This
was most apparent in the increased ratio of wild type (CD45.1) to
IRF-1
-/- (CD45.2) CD8
+ T cells within 12 hours of transfer to
RAG1
-/- mice. Additionally, by 8 days after infection, the ratio of
total wild type (CD45.1) to IRF-1
-/- (CD45.2) CD8
+ T cells
continued to increase. Given that the RAG1
-/- mice are IRF-1
sufficient, this establishes a cell-intrinsic defect in CD8
+ T cell
expansion, and is consistent with bone marrow chimera
reconstitution studies showing that IRF-1
-/- thymocyte maturation
was not restored in irradiated IRF-1
+/+ mice [39]. This phenotype
could be due to altered responsiveness to IL-12, which has been
observed in IRF-1
-/- CD4
+ T cells [43,44], or possibly, other
cytokines (e.g., IL-15 or IL-18) that regulate CD8
+ T cell
proliferation. Alternatively, IRF-1 signaling in antigen presenting
or stromal cells may induce counter-regulatory networks or inhibit
proliferation signals that result in tempered CD8
+ T cell responses.
Consistent with this possible function, we also observed blunted
induction of CD4
+CD25
+FoxP3
+ regulatory T cells in WNV-
infected IRF-1
-/- mice. A deficiency of regulatory T cells was
previously shown to augment antigen-specific CD8
+ T cell
responses after WNV infection [63], although not to the extent
observed in IRF-1
-/- mice.
Within IRF-1
-/- mice we observed an increase in the percentage
and number of WNV-specific CD8
+ T cells at the peak of infection
due to increased proliferation. Our in vitro data supports this
concept as IRF-1
-/- CD8
+ T cells proliferated to a greater extent
than wild type cells after direct stimulation through the T cell
receptor. Interestingly, adoptive transfer of wild type CD8
+ T cells
into an IRF-1
-/- environment suggests that in vivo, a T cell
extrinsic signal can drive the proliferation of antigen-specific cells.
Historically, IRF-1 has been considered a negative regulator of cell
proliferation, which in part explains its tumor suppressive activity
(reviewed in [37]). At present, it remains uncertain as to the
identity of the T cell-extrinsic signal that enhances the prolifer-
ation of antigen-specific cells in IRF-1
-/- mice, although differential
cell-type specific induction of key cytokines (e.g., IL-10 or IL-12)
was not observed (Fig S2).
In summary, our experiments establish that IRF-1 has an
essential function in the innate and adaptive immunity against
WNV infection. In addition to its transduction of IFN-c-
dependent antiviral signals and functions in T cell lineage
commitment in the thymus, IRF-1 appears to directly regulate
antiviral genes in a cell-type specific and IFN-independent manner
and be required for efficient expansion of regulatory T cells.
Moreover, IRF-1 has both cell-intrinsic and -extrinsic functions in
shaping CD8
+ T cell responses, including stimulating both positive
and negative regulatory networks depending on the cell type.
Genetic profiling studies are planned with wild type and IRF-1
-/-
cells to identify novel gene signatures that can help define antiviral
effector and immunomodulatory genes that inhibit viral infections
and shape adaptive T cell responses.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(Assurance Number: A3381-01). All inoculation and experimental
manipulation was performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and all
efforts were made to minimize suffering.
Viruses
The WNV strain (3000.0259) was isolated in New York in 2000
[72] and passaged once in C6/36 Aedes albopictus cells to generate a
stock virus that was used in all experiments.
Mouse experiments
Wild type and congenic RAG1
-/- C57BL/6 mice were obtained
commercially (Jackson Laboratories). C57BL/6.SJL-Ptprc
a/Boy-
AiTac mice were purchased (Taconic) and are congenic with
respect to C57BL/6 mice except at the Ly5.1 (CD45.1) locus. IRF-
1
-/- mice were originally generated by T. Taniguchi [3,34,73] and
obtained on a C57BL/6 background (kindly provided by T.
Taniguchi and K. Fitzgerald). All mice were genotyped and bred
in the animal facilities of the Washington University School of
Medicine under pathogen free conditions, and experiments were
performed in strict compliance with Washington University
Animal Studies guidelines. Eight to twelve week old mice were
used for all in vivo studies. For peripheral infection, 10
2 PFU of
WNV was diluted in Hanks balanced salt solution (HBSS)
supplemented with 1% heat-inactivated fetal bovine serum (FBS)
and inoculated by footpad injection in a volume of 50 ml.
Quantification of tissue viral burden and viremia
To monitor viral spread in vivo, mice were infected with
10
2 PFU of WNV by footpad inoculation and sacrificed at days 1,
2, 4, 6 and 8 after inoculation. After cardiac perfusion with PBS,
organs were harvested, weighed, homogenized and virus was
titrated by standard plaque assay as described [57]. Viremia was
measured by analyzing WNV RNA levels using fluorogenic
quantitative RT-PCR (qRT-PCR) as described [15].
Primary cell culture and viral infection
(a) Macrophages. Bone marrow derived Mw were generated
according to published protocols [6]. Briefly, bone marrow cells
were isolated from mice and cultured for seven days in the
presence of macrophage colony-stimulating factor (M-CSF)
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performed after infection at a multiplicity of infection (MOI) of
0.01 for Mw. Supernatants were titrated by plaque assay on
BHK21 cells. To test for induction of IFN-a and b genes after
WNV infection, 5610
5 Mw were infected at an MOI of 0.1 and
IFN-a and b mRNA was measured by qRT-PCR.
(b) Fibroblasts. Mouse embryo fibroblasts were generated
from wild type and IRF-1
-/- 14-day-old embryos and maintained
in DMEM supplemented with 10% FBS. Cells were used between
passages 2 and 4 for all experiments. Multi-step virus growth
curves were performed after infection at an MOI of 0.001.
Quantification of IFN-a and b mRNA by qRT-PCR
Total RNA was isolated from lymph nodes or primary cells by
using the RNeasy kit according to the manufacturer’s instructions
(Qiagen). During the isolation, to remove any contaminating
DNA, samples were treated with RNAse-free DNAse (Qiagen).
IFN-a and b mRNA were amplified and quantified from total
RNA by qRT-PCR as previously described [47]. The following
primers and probes were used to amplify murine IFN-a and IFN-b
mRNA: IFN-a, forward primer, 59-CTTCCACAGGATCACT-
GTGTACCT-39, reverse primer, 59TTCTGCTCTGACCACC-
TCCC39, probe, 59-FAM-AGAGAGAAGAAACACAGCCCC-
TGTGCC-TAMRA-39; IFN-b, forward primer, 59-CTGGAG-
CAGCTGAATGGAAAG-39, reverse primer, 59-CTTCTCCG-
TCATCTCCATAGGG-39, probe 59-FAM-CAACCTCACCTA-
CAGGGCGGACTTCAAG-TAMRA-39. To analyze the relative
fold induction of IFN-a and IFN-b mRNA, 18S rRNA expression
levels were also determined for normalization by using the Ct
method as described [47].
Measurement of IFN activity by bioassay
Levels of biologically active IFN in serum were measured using
an EMCV L929 cytopathic effect bioassay as described previously
[6]. Results were compared with a standard curve using
recombinant mouse IFN-a (PBL Laboratories).
IFN treatment and neutralization assays
For IFN inhibition assays, wild type or IRF-1
-/- Mw were
pretreated with increasing doses of IFN-b or IFN-c (PBL
Laboratories) for 24 hours and then infected with WNV at an
MOI of 0.1. Supernatants were harvested 48 hours after infection
and titered by plaque assay. For the IFN-c neutralization assay,
various concentrations of exogenous IFN-c were mixed with 20 mg
of a hamster anti-mouse IFN-c neutralizing MAb (H22) [55] or
isotype control for 1 hour at 37uC. Alternatively, wild type Mw
were pretreated with the IFN-c with or without MAbs mixture for
24 hours and then infected with WNV at an MOI of 0.1.
Supernatants were harvested 48 hours post infection and titered
by plaque assay. To test whether H22 (and neutralization of IFN-
c) affected viral replication, multi-step growth curves with wild
type or IRF-1
-/- Mw were performed in the presence of 20 mgo f
H22 antibody or isotype control after infection at an MOI of 0.01.
WNV-specific antibody and CD8
+ T cell responses
The levels of WNV-specific IgM and IgG were determined using
an ELISA against purified WNV E protein [74]. The focus
reduction neutralization assay was performed as described previ-
ously [75]. Intracellular IFN-c or TNF-a staining was performed on
splenocytesusing a previously identified D
b-restrictedNS4B peptide
or K
b-restricted E peptide in a re-stimulation assay with 1 mMo f
peptide and 5 mg/ml of brefeldin A (Sigma) as described [71]. The
number and percentage of CD4
+CD25
+FoxP3
+ regulatory T cells
in the spleen of naı ¨ve or WNV-infected wild type or IRF-1
-/- mice
was measured using the regulatory T cell staining kit (Ebioscience).
Granzyme B (Invitrogen, clone gb12) intracellular staining was
performed without stimulation using the staining solutions for
FoxP3. Intranuclear staining for Ki67 antigen (BD Pharmingen,
clone B56) was performed on CD8
+ T cells ex vivo without
additional stimulation using the FoxP3 staining solutions. In some
experiments WNV-specific CD8
+ T cells were stained with a D
b-
restricted NS4B peptide tetramer (NIH Tetramer Core Facility,
Emory University, Atlanta, GA). Samples were processed by multi-
color flow cytometry on an LSR or FACSCalibur flow cytometer
(Becton Dickinson) and analyzed with FlowJo software (Treestar).
Adoptive transfer experiments
Equal numbers of naı ¨ve donor splenic CD8
+ T cells from wild
type (CD45.1) or IRF-1
-/- (CD45.2) mice were harvested, purified
by negative selection using antibody-coated magnetic beads (anti-
NK1.1, anti-B220, anti-CD4, and anti-MHC class II; Miltenyi
Biotec), and transferred (2610
6 total cells) into recipient RAG1
-/-
mice. One day later mice were bled to confirm the reconstitution,
and then infected with WNV (10
2 PFU via a subcutaneous route).
Eight days later, splenocytes were harvested, and analyzed for
activation and cytokine expression as described above. A similar
procedure was followed for the adoptive transfer of CD8
+ T cells
(2610
6 total cells) from wild type CD45.1 SJL donors into
recipient wild type (CD45.2) or IRF-1
-/- (CD45.2) hosts. Purity of
transferred T cell populations, which ranged from 88 to 92%
CD8b
+, was evaluated by flow cytometry.
To evaluate the ability of activated CD8
+ T cells to reduce viral
burden, wild type and IRF-1
-/- CD8
+ T cells were isolated using
antibody-coated magnetic beads at day 7 after infection and
2610
5 NS4b tetramer
+ cells were adoptively transferred by
intravenous route 48 hours after subcutaneous WNV (10
2 PFU)
infection of 5 week-old wild type mice. Mice were euthanized at
day 6 after infection for analysis of viral burden in the brain by
focus forming assay.
CD3
+ T cell stimulation
Naı ¨ve splenic CD8a
+ T cells were purified from wild type and
IRF-1
-/- mice by positive selection using antibody-coated magnetic
beads (anti-CD8a, Miltenyi Biotec). After purification, CD8
+ T
cells were washed twice with PBS and incubated with 1 mM
carboxyfluorescein diacetate succinimidyl ester in PBS for 10
minutes at 37uC. The reaction was quenched by adding an equal
volume of RPMI 1640 supplemented with 10% FBS, 0.1 mM b-
mercaptoethanol, penicillin, and streptomycin. After washing,
purified labeled CD8
+ T cells (10
6) were plated in individual flat
bottom 96 well tissue culture treated plates in the RPMI medium
described above, in the presence or absence of 1 mM anti-CD3e
(Biolegend, clone 2c11 NA/LE) and 10 mM anti-CD28 (BD
Biosciences, clone 37.51). Cells were harvested at 24, 48 and
72 hours, washed twice with PBS, and analyzed by flow
cytometry.
Leukocyte isolation from CNS
Quantification of infiltrating CNS lymphocytes was performed
as previously described [76]. Briefly, wild type and IRF-1
-/- mouse
brains were harvested on day 8 after infection, dispersed into single
cell suspension with a cell strainer and digested with 0.05%
collagenase D, 0.1 mg/ml trypsin inhibitor TLCK, 10 mg/ml
DNase I and 10 mM of HEPES (Life Technologies) in HBSS for
1 hour. Cells were separated by discontinuous Percoll-gradient
(70/37/30%) centrifugation for 30 min (850 x g at 4uC). Cells
were then counted and stained for CD4, CD8, CD45 and CD11b
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minutes at 4uC, and then fixed with 1% paraformaldehyde. WNV-
specific CD8
+ T cells were identified using a D
b-restricted NS4B
peptide tetramer.
In vivo CD8
+ T cell cytolysis assay
In vivo killing of target cells was performed as previously
described [77]. Briefly, splenocytes from B6.SJL (CD45.1) mice
were isolated. Half of the cells were labeled with carboxyfluor-
escein diacetate succinimidyl ester (CFDA) at 500 nM and the
remainder was labeled with 5 nM CFDA. After labeling, cells
labeled with 500 nM CFDA were pulsed for one hour at 37uC
with 1 mM NS4B 2488-2496 peptide, whereas the 5 nM CFDA
cells were not pulsed with peptide. Both sets of cells were counted
and equal numbers were mixed and injected intravenously (10
7
cells total per mouse) into recipient WNV-infected (at day 8 after
infection) wild type or IRF-1
-/- mice. After 8 hours, the mice were
sacrificed and splenocytes were gated on CD45.1 cells (donor
cells). The percent killing of target cells was calculated: (1 – (ratio
immune/ratio naive)) 6100. Ratio equals the number of NS4B
peptide-coated targets/number of reference targets [77].
Addition of CD8
+ T cells to WNV-infected neurons
Purified CD8
+ T cells were incubated with WNV-infected
cortical neurons as described previously [6]. Briefly, cortical
neurons were isolated and plated onto 24 well plates at 3610
5
neurons per well. Four to five days after plating, neurons were
infected with WNV at an MOI of 0.001 for one hour. Neurons
were washed thrice with warm media and 2610
6 (effector:target
ratio of 10:1) CD8
+ T cells, isolated by positive selection from wild
type or IRF-1
-/- splenocytes at eight days post infection, were
added. Individual wells were harvested at 48 hours after infection,
and WNV titers were measured by focus-forming assay.
Statistical analysis
For in vitro experiments, an unpaired T-test was used to
determine statistically significant differences. For viral burden and
T cell analysis, differences were analyzed by the Mann-Whitney
test. Kaplan-Meier survival curves were analyzed by the log rank
test. All data were analyzed using Prism software (GraphPad
Prism4, San Diego, CA).
Supplemental methods
Additional materials and methods are provided (Text S1).
Supporting Information
Figure S1 CD8
+ NS4b
+ cells express GrB from naı ¨ve and
WNV-infected mice.
(TIF)
Figure S2 Serum cytokines from infected and uninfected wild
type and IRF-1
-/- mice.
(TIF)
Text S1 Supplemental methods.
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